EPS for LSI Industries, Inc. (LYTS) Expected At $0.08; SkyePharma PLC (LON:SKP) Covered By 4 Bulls

July 31, 2017 - By Clifton Ray

Among 4 analysts covering SkyePharma PLC (LON:SKP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SkyePharma PLC had 22 analyst reports since July 30, 2015 according to SRatingsIntel. The rating was maintained by N+1 Singer on Monday, January 11 with “Corporate”. The firm earned “Corporate” rating on Friday, January 8 by N+1 Singer. The firm earned “Corporate” rating on Thursday, July 30 by N+1 Singer. The rating was maintained by N+1 Singer with “Corporate” on Wednesday, October 28. The firm has “Buy” rating given on Wednesday, February 17 by Stifel Nicolaus. As per Wednesday, December 23, the company rating was maintained by RX Securities. The company was maintained on Friday, January 8 by Stifel Nicolaus. As per Monday, August 24, the company rating was maintained by Stifel Nicolaus. The company was maintained on Monday, January 11 by Stifel Nicolaus. The firm has “Corporate” rating given on Wednesday, December 16 by N+1 Singer. See SkyePharma PLC (LON:SKP) latest ratings:

Analysts expect LSI Industries, Inc. (NASDAQ:LYTS) to report $0.08 EPS on August, 17.They anticipate $0.02 EPS change or 33.33% from last quarter’s $0.06 EPS. LYTS’s profit would be $2.03 million giving it 26.19 P/E if the $0.08 EPS is correct. After having $0.01 EPS previously, LSI Industries, Inc.’s analysts see 700.00% EPS growth. About 3,438 shares traded. LSI Industries, Inc. (NASDAQ:LYTS) has declined 23.75% since July 31, 2016 and is downtrending. It has underperformed by 40.45% the S&P500.

Investors sentiment increased to 1.27 in Q4 2016. Its up 0.22, from 1.05 in 2016Q3. It is positive, as 7 investors sold LSI Industries, Inc. shares while 26 reduced holdings. 9 funds opened positions while 33 raised stakes. 19.40 million shares or 0.76% more from 19.26 million shares in 2016Q3 were reported. Pnc Fincl Serv Grp invested 0% of its portfolio in LSI Industries, Inc. (NASDAQ:LYTS). 2,132 are held by Panagora Asset Mgmt. Blackrock Ltd Limited Liability Company invested in 0% or 95,336 shares. Geode Cap Management Llc stated it has 187,070 shares or 0% of all its holdings. Vanguard Grp has 913,394 shares. D E Shaw owns 18,140 shares for 0% of their portfolio. Dimensional Fund Advsr L P holds 1.74 million shares or 0.01% of its portfolio. Secor Capital Advsr Lp has 50,653 shares for 0.06% of their portfolio. Northern Corporation reported 272,900 shares. Wealthtrust Axiom Lc accumulated 761,697 shares or 2.7% of the stock. Cove Street Ltd Llc has invested 0.11% in LSI Industries, Inc. (NASDAQ:LYTS). Amp Capital Investors Ltd reported 17,823 shares. Susquehanna Gp Llp reported 33,756 shares. The New York-based New York State Common Retirement Fund has invested 0% in LSI Industries, Inc. (NASDAQ:LYTS). 14,142 were reported by Deutsche Fincl Bank Ag.

Since March 7, 2017, it had 0 buys, and 3 insider sales for $1.57 million activity. SFERRA JAMES P/ also sold $57,551 worth of LSI Industries, Inc. (NASDAQ:LYTS) shares.

LSI Industries Inc. is a provider of corporate visual image solutions to the petroleum/convenience store industry. The company has market cap of $212.85 million. The Firm creates and develops aspects of the solid-state light emitting diode lighting, from the electronic circuit board, to the software to drive and control the LEDs, to the structure of the LED product. It has a 58.18 P/E ratio. It operates through three divisions: Lighting, Graphics and Technology.

Among 3 analysts covering LSI Industries (NASDAQ:LYTS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. LSI Industries had 4 analyst reports since August 22, 2015 according to SRatingsIntel. The rating was initiated by Roth Capital on Thursday, August 25 with “Buy”. TH Capital initiated it with “Buy” rating and $14 target in Thursday, August 25 report. The firm has “Buy” rating by Sidoti given on Thursday, February 11. The firm has “Hold” rating given on Saturday, August 22 by TheStreet.

Skyepharma Ltd, formerly Skyepharma PLC, is a drug delivery firm engaged in the development of oral and inhalation products. The company has market cap of 470.25 million GBP. The Firm operates as an independent developer of complex pharmaceutical products for global markets. It has a 18.1 P/E ratio. The Company’s principal activities are the generation and development of product and drug delivery technology concepts, involving the application of its inhalation and oral technologies.

It is down 0.00% since July 31, 2016 and is . It has underperformed by 16.70% the S&P500.